• Vistagen Therapeutics Inc VTGN.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of three analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -49 cents to -44 cents per share.

• Revenue rose 190.5% to $244.00 thousand from a year ago; analysts expected $650.00 thousand.

• Vistagen Therapeutics Inc's reported EPS for the quarter was a loss of 47 cents​.

• The company reported a quarterly loss of $15.1 million.

• Vistagen Therapeutics Inc shares had risen by 48.5% this quarter and gained 0.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.4% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $12.00, about 77.3% above its last closing price of $2.73

This summary was machine generated from LSEG data August 8 at 04:21 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)